Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Camillo Porta

Showing results (141-150 of 388) with videos related to

Pageof 39
Sort By:
Cancer Treatment Reviews|February 12, 2020
Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugsStefano Fogli, Camillo Porta, Marzia Del Re, et al.
Rare Tumors|October 23, 2012
Lingual metastasis from renal cell carcinoma: a case report and literature reviewCarlo Ganini, Angioletta Lasagna, Elisa Ferraris, et al.
Oncology Reports|September 24, 2019
Metastatic renal cell carcinoma cells growing in 3D on poly‑D‑lysine or laminin present a stem‑like phenotype and drug resistanceKlaudia K Brodaczewska, Zofia F Bielecka, Kamila Maliszewska-Olejniczak, et al.
Therapeutic Advances in Medical Oncology|August 4, 2022
Cabozantinib combination therapy for the treatment of solid tumors: a systematic reviewDaniel Castellano, Andrea B Apolo, Camillo Porta, et al.
Frontiers in Immunology|April 9, 2020
Single-Cell Approaches to Profile the Response to Immune Checkpoint InhibitorsLara Gibellini, Sara De Biasi, Camillo Porta, et al.
Current Medicinal Chemistry|June 10, 2016
Targeting Stim and Orai Proteins as an Alternative Approach in Anticancer TherapyFrancesco Moccia, Estella Zuccolo, Valentina Poletto, et al.
Clinical Genitourinary Cancer|July 3, 2013
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agentsFrancesco Massari, Emilio Bria, Francesca Maines, et al.
Oncology Reports|August 9, 2002
Impact of topotecan-based chemotherapy on the immune system of advanced ovarian cancer patients: an immunophenotypic studySilvia Ferrari, Bianca Rovati, Lucia Cucca, et al.
Journal of Nephrology|October 27, 2015
Glomerular diseases and cancer: evaluation of underlying malignancyAntonello Pani, Camillo Porta, Laura Cosmai, et al.
Cancer Treatment Reviews|March 16, 2024
How to deal with renal toxicities from immune-based combination treatments in metastatic renal cell carcinoma. A nephrological consultation for OncologistsMarcello Tucci, Laura Cosmai, Marta Pirovano, et al.
Pageof 39

Showing results (141-150 of 388) with videos related to

Sort By:
Pageof 39
Cancer Treatment Reviews|February 12, 2020
Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugsStefano Fogli, Camillo Porta, Marzia Del Re, et al.
Rare Tumors|October 23, 2012
Lingual metastasis from renal cell carcinoma: a case report and literature reviewCarlo Ganini, Angioletta Lasagna, Elisa Ferraris, et al.
Oncology Reports|September 24, 2019
Metastatic renal cell carcinoma cells growing in 3D on poly‑D‑lysine or laminin present a stem‑like phenotype and drug resistanceKlaudia K Brodaczewska, Zofia F Bielecka, Kamila Maliszewska-Olejniczak, et al.
Therapeutic Advances in Medical Oncology|August 4, 2022
Cabozantinib combination therapy for the treatment of solid tumors: a systematic reviewDaniel Castellano, Andrea B Apolo, Camillo Porta, et al.
Frontiers in Immunology|April 9, 2020
Single-Cell Approaches to Profile the Response to Immune Checkpoint InhibitorsLara Gibellini, Sara De Biasi, Camillo Porta, et al.
Current Medicinal Chemistry|June 10, 2016
Targeting Stim and Orai Proteins as an Alternative Approach in Anticancer TherapyFrancesco Moccia, Estella Zuccolo, Valentina Poletto, et al.
Clinical Genitourinary Cancer|July 3, 2013
Adjuvant treatment for resected renal cell carcinoma: are all strategies equally negative? Potential implications for trial design with targeted agentsFrancesco Massari, Emilio Bria, Francesca Maines, et al.
Oncology Reports|August 9, 2002
Impact of topotecan-based chemotherapy on the immune system of advanced ovarian cancer patients: an immunophenotypic studySilvia Ferrari, Bianca Rovati, Lucia Cucca, et al.
Journal of Nephrology|October 27, 2015
Glomerular diseases and cancer: evaluation of underlying malignancyAntonello Pani, Camillo Porta, Laura Cosmai, et al.
Cancer Treatment Reviews|March 16, 2024
How to deal with renal toxicities from immune-based combination treatments in metastatic renal cell carcinoma. A nephrological consultation for OncologistsMarcello Tucci, Laura Cosmai, Marta Pirovano, et al.
Pageof 39